The Senior Leadership is the central decision-making and internal advisory body, with the goal to encourage research productivity, promote interaction and collaboration, and take maximum advantage of institutional strengths and unique scientific opportunities. As Director, Dr. Donald Trump has broad authority over all aspects of the Cancer Center, and he is the ultimate visionary and decision-maker for scientific and administrative matters. The Deputy Director and Associate Directors are accomplished, productive scientists, having served on study sections, as well as important national advisory boards. The Senior Leaders are: Dr. Donald Trump, Director (recruited in 2002, appointed Director in 2007);Dr. Candace Johnson, Deputy Director (recruited in 2002, appointed in 2008);Dr. Alex Adjei, Associate Director for Clinical Research (2006);Dr. Andrei Gudkov, Associate Director for Basic Research (2007);Dr. Richard Hershberger, Chief Academic Officer (2011);Dr. James Marshall, Associate Director of Population Sciences Research (2002);Dr. James Mohler, Associate Director for Translational Research (recruited 2003, appointed 2008);and Brian Springer, Associate Director for Administration (2011). Each of the Senior Leaders also plays a pivotal role in CCSG Programs, Shared Resources, and/or administrative services. This team works closely and collaboratively to integrate RPCI research efforts, promote transdisciplinary interaction and collaboration, and set strategic direction and priorities. The leaders place specific emphasis on moving basic science research through the translational pipeline using internal and external mechanisms, as well as research focused within the RPCI catchment area. The leadership team builds and develops training and education programs to prepare future generations of cancer scientists. Over this funding cycle (2008 to 2013) and in accordance with the strategic plan, the Senior Leadership team worked together to recruit more than 137 cancer investigators and clinicians, of whom 51 are CCSG members. The group's emphasis on developing outstanding basic, translational, clinical, population science led to a 17% increase in peer-reviewed funding from $60.5 to $70.8 million. Efforts for development of investigator-initiated trials, resulted in an increase in institutional intervention accrual from 546 (2008) to 620 (2012), with institutional accrual rising from 60.3% to 71.3% of overall interventional accrual.

Public Health Relevance

RPCI Senior Leadership works effectively to manage the Cancer Center Support Grant, establish the overall direction and plan strategically for the Institute. The leaders are responsible for clinical, basic and translational research efforts across all programmatic areas seeking to understand, prevent and cure cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-37
Application #
8738378
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-06-16
Project End
2019-04-30
Budget Start
2014-06-26
Budget End
2015-04-30
Support Year
37
Fiscal Year
2014
Total Cost
$149,186
Indirect Cost
$59,009
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035
Dasgupta, Subhamoy; Rajapakshe, Kimal; Zhu, Bokai et al. (2018) Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 556:249-254
La Shu, Shin; Yang, Yunchen; Allen, Cheryl L et al. (2018) Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. Sci Rep 8:12905
Zhang, Dingxiao; Tang, Dean G; Rycaj, Kiera (2018) Cancer stem cells: Regulation programs, immunological properties and immunotherapy. Semin Cancer Biol 52:94-106
Gabriel, Emmanuel; Attwood, Kristopher; Al-Sukhni, Eisar et al. (2018) Age-related rates of colorectal cancer and the factors associated with overall survival. J Gastrointest Oncol 9:96-110
Ma, Wen Wee; Xie, Hao; Fetterly, Gerald et al. (2018) A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol :
Chen, George L; Carpenter, Paul A; Broady, Raewyn et al. (2018) Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 24:373-380
Eng, Kevin H; Szender, J Brian; Etter, John Lewis et al. (2018) Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. PLoS Genet 14:e1007194
Barger, Carter J; Zhang, Wa; Sharma, Ashok et al. (2018) Expression of the POTE gene family in human ovarian cancer. Sci Rep 8:17136
Bucsek, Mark J; Giridharan, Thejaswini; MacDonald, Cameron R et al. (2018) An overview of the role of sympathetic regulation of immune responses in infectious disease and autoimmunity. Int J Hyperthermia 34:135-143

Showing the most recent 10 out of 1555 publications